HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 280, Issue 16, 15767-15772, April 22, 2005

This Article Abstract Full Text (PDF) All Versions of this Article: 280/16/15767    most recent M500451200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schönherr, E. Articles by Schaefer, L. Search for Related Content PubMed PubMed Citation Articles by Schönherr, E. Articles by Schaefer, L. Social Bookmarking                      What's this?

Decorin, a Novel Player in the Insulin-like Growth Factor System^*

Elke Schönherr¶, Cord Sunderkötter||**, Renato V. Iozzo, and Liliana Schaefer

From the Matrix Biology and Tissue Repair Research Unit, Cardiff University Dental School, Cardiff CF14 4XY, United Kingdom, Institute of Physiological Chemistry and Pathobiochemistry, ^||Institute of Experimental Dermatology and Department of Dermatology, and the Department of Internal Medicine D, University and University Hospital of Münster, D-48149 Münster, Germany, the Department of Pathology, Anatomy, and Cell Biology and the Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-6799, and the ^**Department of Dermatology, University and University Hospital of Ulm, D-8901 Ulm, Germany

Received for publication, January 13, 2005

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Decorin is a multifunctional proteoglycan that is expressed by sprouting endothelial cells. Its expression supports capillary formation and cell survival. Previously, it was shown that some effects of decorin are mediated by protein kinase B and the cyclin-dependent kinase inhibitor, p21. However, the cell surface receptor responsible for these effects was unknown. We demonstrate that decorin binds to the insulin-like growth factor-I (IGF-I) receptor on endothelial cells with an affinity in the nanomolar range (K_D = 18 nM), which is comparable with IGF-I (K_D = 1.2 nM). Furthermore, decorin can bind IGF-I itself, but with a lower affinity (K_D = 190 nM) than classical IGF-I-binding proteins. Decorin addition causes IGF-I receptor phosphorylation and activation, which is followed by receptor down-regulation. These effects are caused by the core protein of decorin, and the binding region could be mapped to the N terminus of the molecule. The physiological relevance of the decorin/IGF-I receptor interaction was corroborated in two animal models (e.g. inflammatory angiogenesis in the cornea and unilateral ureteral obstruction). In both models the IGF-I receptor was up-regulated in decorin-deficient mice compared with controls and the up-regulation could not compensate the decorin deficiency in the disease models. These data indicate that decorin is an important player in the IGF system and its loss cannot fully be compensated in different types of diseases.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Decorin is the most thoroughly investigated member of the still growing family of small leucine-rich proteoglycans. Core proteins of these proteoglycans are characterized by leucine-rich repeat motifs flanked by cysteine-rich clusters. In addition, they carry at least a single glycosaminoglycan chain. Recently, a crystal structure for bovine decorin has been published (1) that together with earlier x-ray scattering data (2) suggests that decorin is a dimeric protein with 12 leucine-rich repeat motifs that include the N- and C-terminal cysteine-rich regions. This numbering of leucine-rich repeats is subsequently used in this report. Each monomer adopts a curved structure, and an antiparallel dimerization occurs through the -sheet on the concave surface of the monomer. Decorin has been shown to have a variety of different functions that can be mediated by the core protein as well as the glycosaminoglycan chain. It regulates collagen fibril formation and stabilization, and it modulates cell adhesion as well as transforming growth factor- activity (for review see Refs. 3 and 4). More recently it was found to influence directly the behavior of several types of cells. It can interact with members of the ErbB receptor family in tumor cells where it leads to a more differentiated phenotype (5) or to apoptosis of these cells (6). Decorin expression in endothelial cells, hepatocytes, fibroblasts, or macrophages causes differentiation, but it does not lead to apoptosis. In contrast, it protects cells from programmed cell death (6–8).

Endothelial cells cultured inside a collagen lattice can form capillary-like structures. We showed that both capillary formation and protection from apoptosis were only observed in decorin-synthesizing cells. A decorin-containing matrix was not sufficient to induce these changes. Adenoviral gene transfer of decorin into endothelial cells confirmed that decorin was instrumental for tube formation and cell survival (7). The physiological and pathophysiological relevance of these observations in culture was further supported by the finding that interleukin-6 and -10, two cytokines that are released during inflammation, induce decorin synthesis in endothelial cells growing in a collagen lattice (9). These cell culture results corroborate earlier observations in vivo, where decorin was found during inflammation-induced angiogenesis, i.e. in newly formed capillaries in granulomatous tissue (7) or in neovessels in temporal arteritis, but not in capillaries of the ovary in different phases of follicle and corpus luteum formation (10). The importance of decorin in angiogenesis could also be demonstrated in a model of inflammatory angiogenesis in the cornea, as blood vessel growth was significantly reduced in decorin knock-out mice compared with wild-type mice (11). However, decorin signaling is involved not only in angiogenesis but also in renal inflammation and fibrosis, as enhanced apoptosis and atrophy of tubular epithelial cells as well as an increased infiltration of mononuclear cells were observed in unilateral ureteral obstruction (UUO)¹ in decorin-deficient mice (12).

How decorin affects differentiation and apoptosis is not completely understood. In tumor cells, decorin binds to the epithelial growth factor (EGF) receptor or ErbB4 and leads to activation of the mitogen-activated kinase (MAPK) pathway, Ca²⁺ influx, induction of the cyclin-dependent kinase inhibitor, p21, and subsequently to down-regulation of the receptor (13–15). In endothelial cells decorin affects different pathways. It enhances the phosphorylation of protein kinase B (Akt) and subsequently induces p21 by a MAPK-independent pathway. In addition to p21 the related cyclin-dependent kinase inhibitor, p27, is also induced, but by an Akt- and MAPK-independent mechanism (16).

In this study we have searched for potential cell surface receptors that could be involved in decorin signaling. Inhibitor studies indicated that the insulin-like growth factor-I receptor (IGF-IR) was a likely candidate. The IGF-IR is a ligand-activated tyrosine protein kinase highly homologous to the insulin receptor. It consists of a heterotetramer (22) linked by disulfide bridges. Via its extracellular 2 units, the receptor binds IGF-I and IGF-II with high affinity. This interaction leads to autophosphorylation of the receptor and downstream proteins, including insulin receptor substrate-1. In the next step phosphoinositide 3-kinase is activated, which increases the levels of phosphoinositol-3,4,5-trisphosphate. Phosphoinositol-3,4,5-trisphosphate binds to the pleckstrin homology domains of phosphoinositide-dependent kinase I and Akt, thereby initiating the phosphorylation of Akt and several other signaling molecules such as protein kinases C and A. These signaling events finally lead to the inhibition of pro-apoptotic factors, the activation of survival factors, and cell differentiation or proliferation, depending on the cell type and tissue investigated (Ref. 17 and references therein). The general importance of the IGF-IR is implicated by the phenotype of IGF-IR knock-out mouse, which exhibits severe growth retardation and dies at birth (18). IGF-I is mainly produced by the liver, but expression in other types of tissue has been shown (19). The availability of IGF-I and IGF-II for receptor binding is regulated extracellularly by six high affinity-binding proteins and several low affinity-binding proteins. In addition, some of the IGF-binding proteins can exert biological functions independently of their role in the IGF system (20).

In this report we show for the first time that decorin can bind the IGF-IR and also interacts with IGF-I itself. This interaction regulates IGF signaling and may be responsible for the retardation of angiogenesis in the cornea of decorin knock-out mice and for the atrophy in later stages of tubulointerstitial fibrosis observed after UUO in these mice.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Materials—Antibodies used were sc-713 (Santa Cruz Biotechnologies) against the -chain of the IGF-IR, rabbit anti-phospho-Akt (T308), rabbit anti-Akt (Cell Signaling Technologies, Beverly MA), and rat anti-CD31 (ERMP12; BMA Biomedical, Augst, Switzerland). Secondary antibodies labeled with horseradish peroxidase used were porcine anti-rat immunoglobulin (DAKO, Hamburg, Germany), goat anti-rabbit-IgG (Bio-Rad), and horse anti-mouse IgG (Alexis, Grüneberg, Germany). Tyrphostin AG1048 and AG1478 were obtained from Alexis. IGF-I and chemicals not specifically indicated were purchased from Sigma. Decorin and its mutants were purified from conditioned medium from HEK-293 cells or human skin fibroblasts as previously described (21). The purity of the preparation was checked by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and silver staining.

Cell Culture—Cells of the permanent human endothelial cell line EA.hy 926 (22) were permanently grown in MCDB 131 supplemented with 10% fetal calf serum, hypoxanthin/aminopterin/thymidine supplement, and antibiotics (all from Invitrogen). Hydrophilic cell culture dishes (3 cm) were coated with a neutralized collagen mixture (7). After collagen gel formation (30 min, 37 °C), EA.hy 926 (500,000 cells) were plated on this substrate in 1 ml of Waymouth MAB 87/3 medium containing 1% heat-inactivated fetal calf serum. After 5 h of culture, 1 ml of medium without serum was added. After 48 h, decorin and/or the respective inhibitors were added, and cells were harvested at the indicated times. Adenoviral infections were performed as previously described (7, 16).

Immunoblotting—For the detection of phosphorylated proteins, cells from a 3-cm-dish were harvested in 100 µl of cold lysis-buffer (10 mM sodium phosphate, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM sodium vanadate, proteinase inhibitors) and sonicated. Aliquots (equal protein concentration/lane) were applied on SDS-PAGE gels. In addition, immunoprecipitations with sc-713 were carried out (described below), and precipitated proteins were separated by SDS-PAGE. After transfer to nitrocellulose, proteins were detected as previously described (7). For the detection and quantification of IGF-IR in mouse kidneys, homogenates of whole kidneys were prepared and applied to SDS-PAGE as previously described (12). Western blots were performed using sc-713 according to the recommendations of the manufacturer. An antibody to -tubulin was used as control for equal loading. Bands were quantified with the ImageQuant 5.0 software program (Amersham Biosciences).

Binding Studies—Decorin (20 µg) and IGF-I (2 µg) were labeled with ¹²⁵I[iodine] and IODO-BEADs (PerBio, Bonn, Germany) according to the manufacturer's instructions. Decorin had a specific activity of 375,000 cpm x mol^–12 and IGF-I of 100,000 cpm x mol^–12.

Decorin (10 µg) with and without chondroitin ABC lyase digestion (Seikagaku Kogyo, Tokyo, Japan) was separated by SDS-PAGE and transferred to nitrocellulose. Blots were blocked for 2 h with 50 mM Tris/HCl, pH 7.4, 3% Nonidet P-40, 0.5 mg/ml NaN₃ and probed with ¹²⁵I-IGF-I in binding buffer (50 mM Tris/HCl, pH 7.4, 0.1% Tween 20, 1 mg/ml bovine serum albumin) overnight at 4 °C. After washing with binding buffer the nitrocellulose was dried and exposed to x-ray films (X-OMAT; Kodak). A Sepharose CL-4B gel filtration column (20 cm long) was equilibrated with binding buffer with or without decorin, and ¹²⁵I-IGF-I (500,000 cpm) was applied. The elution profiles were monitored by scintillation counting.

To determine binding of decorin to the IGF-IR, the receptor was immunoprecipitated from EA.hy 926 cells (7 x 10⁶ cells) with antibody sc-713. Cells were harvested in lysis buffer, and a complex of normal rabbit serum bound to protein A-Sepharose was added for 6 h to remove non-specifically binding proteins. Then 10 µg of the anti-IGF-IR were added, and after 16 h the antibodies were precipitated with protein A-Sepharose. As control, a similar amount of protein A-Sepharose was incubated with the antibody but without cell lysate. After washing (3 x lysis buffer, 2 x phosphate-buffered saline), the material was divided in 7 aliquots and incubated in 250 µl of Tris-buffered saline, 0.1% bovine serum albumin, 0.1% Tween 20 with labeled decorin or IGF-I (as indicated). For competition experiments unlabeled wild type decorin or mutants were added together with the labeled molecules. Immune complexes without receptor were used as controls. After washing five times with binding buffer, bound protein was removed by boiling in 1% SDS and aliquots were counted in a scintillation counter. Dissociation constants were determined with GraphPad Prism3 software using the subroutine for fitting one site binding curves (GraphPad software, San Diego, CA).

Binding of decorin to IGF-I was determined with ¹²⁵I-decorin in a solid phase assay. Shortly, IGF-I (4 µg/ml, 50 µl/well) was used for coating microtiter plates (Immobilon 2; Dynatec); after blocking with Tris-buffered saline, 3% bovine serum albumin, 0.05% Tween 20 for 4 h, labeled decorin was applied in the same buffer (4 h, 37 °C). After washing, the bound material was released and measured by scintillation counting. Dissociation constants were determined as described above.

Animal Experiments—All animal work was done in accordance with the German Animal Protection Law. Decorin-deficient mice were generated as described previously (23). Angiogenesis assays in mice were performed by chemical cauterization of the cornea as described (11). The eyes were removed and fixed in 4% phosphate-buffered paraformaldehyde for paraffin embedding. Unilateral uretral obstractions were done as in previous experiments (12). For the quantification of the IGF-IR, whole kidneys were homogenized in 1 ml of extraction buffer (final volume), and equal volumes were applied for SDS-PAGE. The protein content/aliquot of ligated kidneys was 50 µg, and the protein content/aliquot of unligated kidney was 80 µg/lane. Equal volumes were applied because the kidneys change their weight during the procedure and equal volumes reflect more accurately the situation in the organ. Western blots were carried out as described elsewhere (12) with the exception that the blots were incubated with the antibody sc-713 (1:500) against IGF-IR as primary antibody overnight at 4 °C. Immunohistochemistry was performed as described elsewhere (11, 12).

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Previous experiments have shown that decorin can induce tube formation in endothelial cells and inhibit apoptosis. The phosphorylation of Akt was one step in the pathway(s) (16), but the cell surface receptor for decorin in endothelial cells was unknown. To analyze how decorin activates Akt, different receptor tyrosine kinase inhibitors were tested. The EGF receptor inhibitor tyrphostin AG1478 (10 µM) had no effect on decorin-induced Akt phosphorylation in endothelial cells, but preincubation with tyrphostin AG1024 (10 µM), an inhibitor of the insulin receptor and the IGF-IR tyrosine kinase, was able to inhibit Akt phosphorylation (Fig. 1A) and p21 expression (result not shown).

View larger version (32K): [in this window] [in a new window]   FIG. 1. Effects of decorin on the IGF-IR in endothelial cells. A, endothelial cells (EA.hy 926) were grown on fibrillar collagen in the presence of 0.5% heat-inactivated fetal calf serum for 48 h. After pre-incubation with the indicated inhibitors for 1 h, decorin (80 µg/ml) was added for 10 min. Cells were harvested, and equal amounts of protein were separated by SDS-PAGE. Phosphorylation of Akt at Thr-308 was determined by Western blotting. Only the IGF-IR/insulin receptor-specific inhibitor (AG1024), not the EGF receptor-specific reagent (AG1478), inhibited phosphorylation. B, EA.hy 926 cells (3 x 10–6) were cultured as in panel A, and IGF-I (100 ng/ml) or decorin (80 µg/ml) was added for 4 min. Immunoprecipitations for the IGF-IR were carried out with antibody sc-713. The precipitates were separated by SDS-PAGE, and Western blots were probed for phophotyrosine (pY), the tyrosine kinase activation-specific phosphorylation site at Tyr-1131, and IGF-RI itself. Decorin leads to a strong tyrosine phosphorylation and activation of the IGF-IR. C, EA.hy 926 cells were infected with an adenoviral vector for decorin (AdvDCN) and a control virus (AdvCo) and seeded after 24 h on fibrillar collagen. After 2 and 4 days, the medium and the cells were harvested. Decorin in the medium was determined after anion exchange chromatography and Western blotting with an antibody specific for human decorin. Aliquots of cells (40 µg of protein/lane) were separated by SDS-PAGE, and IGF-IR and -tubulin (control for loading) were determined by Western blotting. Decorin down-regulates the IGF-IR in endothelial cells.

To investigate whether decorin and IGF-I interfere with each other's effects on downstream signals, two types of experiments were performed. In one type, optimal concentrations of IGF-I (100 ng/ml) and decorin (80 µg/ml) were combined and added together to endothelial cells; in the second type of experiment, cells were preincubated at 4 °C with decorin or IGF-I and then the alternative ligand was added for 10 min at 37 °C. Neither of these experiments (n = 2) led to a significant decrease or increase in IGF-IR or Akt phosphorylation compared with the addition of a single ligand at optimal concentration (result not shown).

To investigate whether decorin can down-regulate the IGF-IR, we used a replication-deficient adenovirus containing the human decorin cDNA to induce decorin expression. Previous studies had shown that decorin-mediated effects were observed 2 days after infection and subsequent culture of endothelial cells in a collagen lattice (16). Therefore, endothelial cells treated with a decorin-containing adenovirus or control virus were harvested after 2 and 4 days of culture on a collagen lattice. The IGF-IR was expressed in cells treated with the control virus, whereas overexpression of decorin drastically reduced the amount of receptor found in the cells after 2 days, when the decorin expression reached its peak. There was no recovery after prolonged decorin expression for 4 days (Fig. 1C). These data show that decorin leads to a sustained down-regulation of the IGF-IR.

To characterize which part of the decorin core protein is important for signaling, Akt phosphorylation and/or p21 induction were analyzed after decorin mutants were applied to endothelial cells. For these experiments the following mutants were used: DCN-Q153, a mutant that contains the N terminus and the first 5 leucine-rich repeats of decorin, and DCN-E180K, a mutant with a point mutation reducing its affinity to collagen type I (21). These two mutants were chosen because previous studies (15) had shown that the N-terminal part of decorin is not involved in binding the EGF receptor but leucine-rich repeat 7, which contains the point mutation (DCN-E180K). Our investigation demonstrated that DCN-Q153 alone was still able to induce Akt phosphorylation (Fig. 2A) and p21 expression (result not shown), albeit to a lesser extent than wild type decorin. DCN-E180K induced p21 as strongly as wild type decorin, and it also triggered its translocation to the nucleus (Fig. 2B). These results imply that a different part of the decorin core protein interacts with the IGF-IR than with the EGF receptor.

View larger version (35K): [in this window] [in a new window]   FIG. 2. Effects of decorin mutants on Akt and p21 in endothelial cells. A, EA.hy 926 cells were plated as in Fig. 1A. Wild type decorin (40 µg/ml 1 µM) or DCN-Q153 (25 µg/ml 2 µM) were added for 10 min. Akt phosphorylation was determined as in Fig. 1A. The fragment DCN-Q153 is sufficient to induce Akt phosphorylation. B, EA.hy 926 cells were plated as in Fig. 1A. Wild type decorin or DCN-E180K (both 80 µg/ml) was added to the cells. After 20 h, cells were harvested and nuclear (N) and cellular (C) fractions were prepared. The cyclin-dependent kinase inhibitor, p21, and -tubulin were determined by Western blotting. The mutant DCN-E180K induces p21 synthesis and translocation to the nucleus as efficiently as wild type decorin.

View larger version (24K): [in this window] [in a new window]   FIG. 3. Interaction of decorin with the IGF-IR. A, silver-stained SDS-PAGE of purified decorin. Decorin (2 µg of protein/lane, DCN) with and without chondroitin ABC lyase (ABCase) digestion was run under reducing conditions on a SDS-gradient gel (4–12%). ABCase alone was run as control. Arrows indicate the proteoglycan (PG) and the core protein (core). B–D, IGF-IR was immunoprecipitated from EA.hy 926 cells. Each data point contained immunocomplexes with receptor from 1 x 106 cells. Complexes of antibody without bound receptor were used as controls. Iodinated decorin and IGF-I were bound to these complexes at 4 °C, overnight. Bound ligand was determined by scintillation counting. B, binding curve of 125I-IGF-I. C, binding curve of 125I-decorin. D, 125I-IGF-I was added to the immune complex, which leads to binding of 625 fmol IGF-I (= 100%). Competitions were done as described above in the presence and absence of the indicated amounts of competitor. The dashed line indicates 50% inhibition. IGF-I, black triangles; decorin black circles; DCN-Q153, open circles. Error bars indicate S.E. Both wild type and truncated decorin compete with IGF-I in the same quantitative range.

View larger version (26K): [in this window] [in a new window]   FIG. 4. Interaction of decorin with IGF-I. Complex formation in solution. A gel filtration column (Sepharose CL-4B) was equilibrated without decorin (squares), 2 µg/ml (triangles), 5 µg/ml decorin (circles), and 125I-IGF-I (500,000 cpm) was applied. Increasing amounts of decorin lead to the formation of a higher molecular mass complex. Insert, a blot with decorin proteoglycans (97 kDa) and core protein (45 kDa) was incubated with 125I-IGF-I. Decorin binds IGF-I with its core protein. The glycosaminoglycan chain is not necessary for binding.

View larger version (130K): [in this window] [in a new window]   FIG. 5. Up-regulation of IGF-IR in two different animal models. A–D, neovessels in the cornea of decorin-deficient mice. Paraffin sections of corneas (96 h after injury by chemical cauterization) were prepared from Dcn–/– mice (A, C) and wild type mice (B, D). Staining for CD31, as marker for endothelial cells (red; A, B) and for IGF-IR (brown; C, D). There are fewer blood vessels in the Dcn–/– mouse, and there is stronger staining for IGF-IR. Staining for IGF-IR is found in endothelial cells, in the epithelium, and in cells accompanying the invading endothelial cells. In addition, the number of IGF-IR-positive cells was also higher in Dcn–/– than in wild type mice. Arrows indicate corresponding vessel in the parallel sections. E–H, tubuloepithelial cells after unilateral ureteral obstruction of the kidney in decorin-deficient mice. Paraffin sections from kidneys of Dcn–/– (E, G) and wild type mice (F, H) were stained for IGF-IR. 7 days after ligation, unligated, control kidneys (E, F) and ligated kidneys (G, H) were harvested. IGF-IR is constitutively expressed in the tubuloepithelium and up-regulated after ligation. The expression in the Dcn–/– mouse is increased compared with control animals.

View larger version (35K): [in this window] [in a new window]   FIG. 6. Time-dependent up-regulation of IGF-IR in unilateral uretral obstruction in decorin-deficient mice compared with controls. Western blot for IGF-IR and -tubulin of tissue extracts from ligated and unligated kidneys of wild type and Dcn–/– mice. A, after 7 days, ligated kidneys (n = 3), unligated kidney (n = 1). B, after 14 days, ligated kidneys (n = 3), unligated kidney (n = 1). C, quantitation of IGF-IR in the kidney after UUO (n = 3). Wild type mice (black bars), Dcn–/– mice (white bars). After 7 and 14 days about twice as much IGF-IR was found in Dcn–/– compared with wild type animals.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Furthermore, our binding studies show only a 10-fold lower affinity of decorin to the IGF-IR than IGF-I. This affinity was calculated with the assumption that decorin interacts as a monomer. If a dimeric form of decorin (1) binds to the receptor the dissociation constants will be even closer. Our assays using immunoprecipitated native IGF-IR from the same endothelial cells show a lower affinity (K_D = 1.2 x 10^–9M) for binding of IGF-I to its receptor than the values determined for IGF-I and recombinant soluble IGF-IR previously published (25, 26). These differences may be due to the different methodologies and the presence of the intracellular -subunit that is used for the immunoprecipitation. However, the affinities of decorin and IGF-I to the receptor only differ 10-fold under similar binding conditions, showing that binding of decorin to the IGF-IR on the cell surface of endothelial cells is very likely.

Previous investigations have shown that decorin can interact via its core protein with the EGF receptor and the ErbB4 receptor (5, 15). In the case of the EGF receptor the binding has been investigated in more detail, and a stretch of amino acids in the L2 domain of the extracellular EGF binding site (H394-I402) was identified as critical for the interaction. On the decorin core protein, a binding region comprising leucine-rich repeat 7 was identified (15). The IGF-I binding domain of the IGF-IR is structurally related to the binding domain of the EGF receptor (27), but in the homologous region of the L2 domain of the IGF-IR (Phe-371-Leu-377) compared with the L2 domain of the EGF receptor (His-394-Ile-402) the acidic amino acids (Glu-397, Glu-400; EGF receptor) are substituted by basic amino acids (Lys-373, Arg-376; IGF-IR), indicating that this stretch of amino acids in the IGF-IR may have different properties. In addition, the site of interaction for the IGF-RI on the decorin core protein is very likely to be different. We showed that the truncated DCN-Q153, which only contains the N-terminal 5 leucine-rich repeats, was competing for binding to the IGF-IR with IGF-I almost as efficiently as full-length decorin. This truncated mutant could also induce Akt phosphorylation and p21 expression. Furthermore, we could show that a decorin mutant with a point mutation of glutamate 180 (DCN-E180K), which has been shown to have a reduced affinity to collagen type I (21), induced Akt phosphorylation as effectively as wild type decorin. This mutation is in the region that has been shown to be critically involved in EGF receptor binding (15).

Decorin can also bind to IGF-I itself, but the affinity for IGF-I is 1000-fold below the affinities of the typical IGF-binding proteins (20). Therefore, only in situations in which decorin is expressed abundantly may it compete with the classical binding proteins. We did not test whether decorin-bound IGF-I can interact with collagen, because of the low affinity of the observed interaction.

The physiological relevance of the interaction of decorin with the IGF-IR can be clearly seen in the decorin-deficient mouse. The mouse shows no growth retardation like the IGF-I- or IGF-IR-deficient animals (18), but when the mouse is challenged, as during inflammation-induced angiogenesis in the cornea, blood vessel growth is reduced and the IGF-IR is more strongly up-regulated in capillary-forming endothelial cells and invading cells in decorin-deficient mice than in wild type mice. The importance of IGF-I for angiogenesis has been shown in several different models ranging from normal development (28) to tumor angiogenesis (29) and angiogenesis in the retina (30). Some effects of IGF-I are transmitted by the induction of VEGF (30), but direct activation of downstream signaling of the IGF-IR has also been implicated for cell survival and differentiation (31). Moreover, ligation of kidneys from decorin null mice resulted in enhanced apoptosis of tubular epithelial cells. Simultaneously, a more pronounced up-regulation of IGF-IR occurred in these cells. Increased expression of decorin in ligated kidneys from wild type mice and rats (12, 32), as well as accelerated tubular atrophy and infiltration during UUO in decorin-deficient mice, suggests an important regulatory role of decorin in this model. In agreement with our findings that decorin and IGF-I stimulate a common signaling pathway, treatment of UUO with IGF-I has been shown to reduce tubular apoptosis and atrophy in the neonatal rat (33). The elevated tubuloepithelial expression of IGF-IR protein in ligated kidneys from Dcn–/– mice as compared with wild type animals might represent a compensatory mechanism for the lack of decorin to protect tubular epithelial cells from apoptosis. Not much is known about the expression of IGF-IR protein in the UUO. In terms of IGF-IR mRNA, expression was unchanged up to 7 days of UUO in neonatal rat (33) and markedly down-regulated in hydronephrotic kidneys with fibrotic progression in humans (34).

In conclusion, our findings indicate that decorin can bind both IGF-I and its receptor and that this interaction leads to Akt phosphorylation and p21 induction in endothelial cells. Further studies, however, are needed to clarify whether the interaction of decorin with IGF-I and its receptor is important for other types of diseases in which the IGF system is involved.

	FOOTNOTES

 
^* This work was supported by the Deutsche Forschungsgemeinschaft (SFB 293, Project A7 (to E. S.), SFB 492 B10 (to L. S.), SFB 293, Project A8 (to C. S.)), by the Interdisciplinary Center for Clinical Research of the Medical Faculty of the University of Münster, Germany (Project D15 (to C. S.), D18 and Schae2/004/04 (to L. S.)), IMF SC 11 04 07 (to L. S.), BMBF Fk2 01 GM0310 (to C. S.), National Institutes of Health Grant RO1 CA-39481 (to R. V. I.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ To whom correspondence should be addressed. Tel.: 44-29-2074-2595; Fax: 44-29-2074-4509; E-mail: schonherreh{at}cardiff.ac.uk.

¹ The abbreviations used are: UUO, unilateral ureteral obstruction; Akt, protein kinase B; DCN, decorin; EGF, epithelial growth factor; IGF, insulin-like growth factor; IGF-IR, IGF factor I receptor.

	ACKNOWLEDGMENTS

 
We thank M. Bahl for expert technical help.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Scott, P. G., Grossmann, J. G., Dodd, C. M., Sheehan, J. K., and Bishop, P. N. (2003) J. Biol. Chem. 278, 18353–18359[Abstract/Free Full Text]
2. Scott, P. G., McEwan, P. A., Dodd, C. M., Bergmann, E. M., Bishop, P. N., and Bella, J. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 15633–15638[Abstract/Free Full Text]
3. Kinsella, M. G., Bressler, S. L., and Wight, T. N. (2004) Crit. Rev. Eukaryot. Gene Expression 14, 203–234[CrossRef][Medline] [Order article via Infotrieve]
4. Kresse, H., and Schönherr, E. (2001) J. Cell. Physiol. 189, 266–274[CrossRef][Medline] [Order article via Infotrieve]
5. Santra, M., Eichstetter, I., and Iozzo, R. V. (2000) J. Biol. Chem. 275, 35153–35161[Abstract/Free Full Text]
6. Tralhão, J. G., Schaefer, L., Micegova, M., Evaristo, C., Schönherr, E., Kayal, S., Veiga-Fernandes, H., Danel, C., Aresta, S., Iozzo, R. V., Kresse, H., and Lemarchand, P. (2003) FASEB J. 17, 464–466[Abstract/Free Full Text]
7. Schönherr, E., O'Connell, B. C., Schittny, J., Robenek, H., Fastermann, D., Fisher, L. W., Plenz, G., Vischer, P., Young, M. F., and Kresse, H. (1999) Eur. J. Cell Biol. 78, 44–55[Medline] [Order article via Infotrieve]
8. Xaus, J., Comalada, M., Cardo, M., Valledor, A. F., and Celada, A. (2001) Blood 98, 2124–2133[Abstract/Free Full Text]
9. Strazynski, M., Eble, J. A., Kresse, H., and Schönherr, E. (2004) J. Biol. Chem. 279, 21266–21270[Abstract/Free Full Text]
10. Nelimarkka, L., Salminen, H., Kuopio, T., Nikkari, S., Ekfors, T., Laine, J., Pelliniemi, L., and Järveläinen, H. (2001) Am. J. Pathol. 158, 345–353[Abstract/Free Full Text]
11. Schönherr, E., Sunderkötter, C., Schaefer, L., Thanos, S., Grässel, S., Oldberg, Å., Iozzo, R. V., Young, M. F., and Kresse, H. (2004) J. Vasc. Res. 41, 499–508[CrossRef][Medline] [Order article via Infotrieve]
12. Schaefer, L., Macakova, K., Raslik, I., Micegova, M., Gröne, H. J., Schönherr, E., Robenek H., Echtermeyer, F. G., Grässel, S., Bruckner, P., Schaefer, R. M., Iozzo, R. V., and Kresse, H. (2002) Am. J. Pathol. 160, 1181–1191[Abstract/Free Full Text]
13. DeLuca, A., Santra, M., Baldi, A., Giordano, A., and Iozzo, R. V. (1996) J. Biol. Chem. 271, 18961–18965[Abstract/Free Full Text]
14. Patel, S., Santra, M., McQuillan, D. J., Iozzo, R. V., and Thomas, A. P. (1998) J. Biol. Chem. 273, 3121–3124[Abstract/Free Full Text]
15. Santra, M., Reed, C. C., and Iozzo, R. V. (2002) J. Biol. Chem. 277, 35671–35681[Abstract/Free Full Text]
16. Schönherr, E., Levkau, B., Schaefer, L., Kresse, H., and Walsh, K. (2001) J. Biol. Chem. 276, 40687–40692[Abstract/Free Full Text]
17. Vincent, A. M., and Feldman, E. L. (2002) Growth Horm. IGF Res. 12, 193–197[CrossRef][Medline] [Order article via Infotrieve]
18. Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J., and Efstratiadis, A. (1993) Cell 75, 59–72[Medline] [Order article via Infotrieve]
19. Cohick, W. S., and Clemmons, D. R. (1993) Annu. Rev. Physiol. 55, 131–153[Medline] [Order article via Infotrieve]
20. Mohan, S., and Baylink, D. J. (2002) J. Endocrinol. 175, 19–31[Abstract]
21. Kresse, H., Liszio, C., Schönherr, E., and Fisher, L. W. (1997) J. Biol. Chem. 272, 18404–18410[Abstract/Free Full Text]
22. Edgell, C. J., McDonald, C. C., and Graham, J. B. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 3734–3737[Abstract/Free Full Text]
23. Danielson, K. G., Baribault, H., Holmes, D. F., Graham, H., Kadler, K. E., and Iozzo, R. V. (1997) J. Cell Biol. 136, 729–743[Abstract/Free Full Text]
24. Su, E. J., Cioffi, C. L., Stefansson, S., Mittereder, N., Garay, M., Hreniuk, D., and Liau, G. (2003) Am. J. Physiol. Heart Circ. Physiol. 284, H1429-H1440[Abstract/Free Full Text]
25. Jansson, M., Dixelius, J., Uhlen, M., and Nilsson, B. O. (1997) FEBS Lett. 416, 259–264[CrossRef][Medline] [Order article via Infotrieve]
26. Mynarcik, D. C., Williams, P. F., Schaffer, L., Yu, G. Q., and Whittaker, J. (1997) J. Biol. Chem. 272, 18650–18655[Abstract/Free Full Text]
27. Garrett, T. P., McKern, N. M., Lou, M., Frenkel, M. J., Bentley, J. D., Lovrecz, G. O., Elleman, T. C., Cosgrove, L. J., and Ward, C. W. (1998) Nature 394, 395–399[CrossRef][Medline] [Order article via Infotrieve]
28. Han, R. N., Post, M., Tanswell, A. K., and Lye, S. J. (2003) Am. J. Respir. Cell Mol. Biol. 28, 159–169[Abstract/Free Full Text]
29. Reinmuth, N., Fan, F., Liu, W., Parikh, A. A., Stoeltzing, O., Jung, Y. D., Bucana, C. D., Radinsky, R., Gallick, G. E., and Ellis, L. M. (2002) Lab. Investig. 82, 1377–1389[Medline] [Order article via Infotrieve]
30. Smith, L. E., Shen, W., Perruzzi, C., Soker, S., Kinose, F., Xu, X., Robinson, G., Driver, S., Bischoff, J., Zhang, B., Schaeffer, J. M., and Senger, D. R. (1999) Nat. Med. 5, 1390–1395[CrossRef][Medline] [Order article via Infotrieve]
31. Partovian, C., and Simons, M. (2004) Cell. Signal. 16, 951–957[CrossRef][Medline] [Order article via Infotrieve]
32. Diamond, J. R., Levinson, M., Kreisberg, R., and Ricardo, S. D. (1997) Kidney Int. 51, 1133–1139[Medline] [Order article via Infotrieve]
33. Chevalier, R. L., Goyal, S., Kim, A., Chang, A. Y., Landau, D., and LeRoith, D. (2000) Kidney Int. 57, 882–890[CrossRef][Medline] [Order article via Infotrieve]
34. Henger, A., Kretzler, M., Doran, P., Bonrouhi, M., Schmid, H., Kiss, E., Cohen, C. D., Madden, S., Porubsky, S., Gröne, E. F., Schlöndorff, D., Nelson, P. J., and Gröne, H.-J. (2004) Kidney Int. 65, 904–917[CrossRef][Medline] [Order article via Infotrieve]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				L. Schaefer and R. V. Iozzo Biological Functions of the Small Leucine-rich Proteoglycans: From Genetics to Signal Transduction J. Biol. Chem., August 1, 2008; 283(31): 21305 - 21309. [Abstract] [Full Text] [PDF]

				H. H. Salomaki, A. O. Sainio, M. Soderstrom, S. Pakkanen, J. Laine, and H. T. Jarvelainen Differential Expression of Decorin by Human Malignant and Benign Vascular Tumors J. Histochem. Cytochem., July 1, 2008; 56(7): 639 - 646. [Abstract] [Full Text] [PDF]

				X. Li, A. Pennisi, and S. Yaccoby Role of decorin in the antimyeloma effects of osteoblasts Blood, July 1, 2008; 112(1): 159 - 168. [Abstract] [Full Text] [PDF]

				L. R. Fiedler, E. Schonherr, R. Waddington, S. Niland, D. G. Seidler, D. Aeschlimann, and J. A. Eble Decorin Regulates Endothelial Cell Motility on Collagen I through Activation of Insulin-like Growth Factor I Receptor and Modulation of {alpha}2{beta}1 Integrin Activity J. Biol. Chem., June 20, 2008; 283(25): 17406 - 17415. [Abstract] [Full Text] [PDF]

				Z. Ferdous, V. M. Wei, R. Iozzo, M. Hook, and K. J. Grande-Allen Decorin-transforming Growth Factor- Interaction Regulates Matrix Organization and Mechanical Characteristics of Three-dimensional Collagen Matrices J. Biol. Chem., December 7, 2007; 282(49): 35887 - 35898. [Abstract] [Full Text] [PDF]

				C. Cabello-Verrugio and E. Brandan A Novel Modulatory Mechanism of Transforming Growth Factor-beta Signaling through Decorin and LRP-1 J. Biol. Chem., June 29, 2007; 282(26): 18842 - 18850. [Abstract] [Full Text] [PDF]

				L. Schaefer, W. Tsalastra, A. Babelova, M. Baliova, J. Minnerup, L. Sorokin, H.-J. Grone, D. P. Reinhardt, J. Pfeilschifter, R. V. Iozzo, et al. Decorin-Mediated Regulation of Fibrillin-1 in the Kidney Involves the Insulin-Like Growth Factor-I Receptor and Mammalian Target of Rapamycin Am. J. Pathol., January 1, 2007; 170(1): 301 - 315. [Abstract] [Full Text] [PDF]

				Y. Mochida, D. Parisuthiman, M. Kaku, J.-i. Hanai, V. P. Sukhatme, and M. Yamauchi Nephrocan, a Novel Member of the Small Leucine-rich Repeat Protein Family, Is an Inhibitor of Transforming Growth Factor-beta Signaling J. Biol. Chem., November 24, 2006; 281(47): 36044 - 36051. [Abstract] [Full Text] [PDF]

				E. Brandan, C. Retamal, C. Cabello-Verrugio, and M.-P. Marzolo The Low Density Lipoprotein Receptor-related Protein Functions as an Endocytic Receptor for Decorin J. Biol. Chem., October 20, 2006; 281(42): 31562 - 31571. [Abstract] [Full Text] [PDF]

				A. Hartner, L. Schaefer, M. Porst, N. Cordasic, A. Gabriel, B. Klanke, D. P. Reinhardt, and K. F. Hilgers Role of fibrillin-1 in hypertensive and diabetic glomerular disease Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1329 - F1336. [Abstract] [Full Text] [PDF]

				J.-X. Zhu, S. Goldoni, G. Bix, R. T. Owens, D. J. McQuillan, C. C. Reed, and R. V. Iozzo Decorin Evokes Protracted Internalization and Degradation of the Epidermal Growth Factor Receptor via Caveolar Endocytosis J. Biol. Chem., September 16, 2005; 280(37): 32468 - 32479. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text